Chimerix, Inc. (CMRX)
After hours:
| Previous close | 0.9639 |
| Open | 0.9740 |
| Bid | 0.9624 x 100 |
| Ask | 0.9955 x 100 |
| Day's range | 0.9519 - 0.9799 |
| 52-week range | 0.8800 - 1.5700 |
| Volume | |
| Avg. volume | 308,771 |
| Market cap | 86.654M |
| Beta (5Y monthly) | 1.12 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.9400 |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireChimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference
DURHAM, N.C., May 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Andriole, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 3:00 p.m. ET. An audio webcast of the panel discussion will be available on the Investor Relations secti
Insider MonkeyChimerix, Inc. (NASDAQ:CMRX) Q1 2024 Earnings Call Transcript
Chimerix, Inc. (NASDAQ:CMRX) Q1 2024 Earnings Call Transcript May 1, 2024 Chimerix, Inc. misses on earnings expectations. Reported EPS is $-0.25 EPS, expectations were $-0.21. Chimerix, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies and gentlemen, […]
- GuruFocus.com
Chimerix Inc (CMRX) Q1 2024 Earnings Call Transcript Highlights: Strategic Developments and ...
Insights into Chimerix Inc's financial health, strategic progress in clinical trials, and future plans from the latest earnings call.
